Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in NEUP held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | Lynx1 Capital Management LP | 875K | $3.6M | +0.0% | 16.176% | 0.56% |
| 2 | AdvisorShares Investments LLC | 155K | $632K | +15.8% | 2.871% | 0.12% |
| 3 | Shay Capital LLC | 151K | $615K | -10.7% | 2.791% | 0.05% |
| 4 | BALYASNY ASSET MANAGEMENT LLC | 142K | $579K | β | 2.627% | 0.00% |
| 5 | Squadron Capital Management LLC | 77K | $312K | β | 1.418% | 0.13% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 52K | $212K | +200.6% | 0.961% | 0.00% |
| 7 | Ikarian Capital, LLC | 47K | $193K | 0.0% | 0.877% | 0.02% |
| 8 | ADAR1 Capital Management, LLC | 30K | $122K | 0.0% | 0.554% | 0.01% |
| 9 | CITADEL ADVISORS LLC | 19K | $79K | β | 0.357% | 0.00% |
| 10 | BOOTHBAY FUND MANAGEMENT, LLC | 14K | $57K | 0.0% | 0.259% | 0.00% |
| 11 | COMMONWEALTH EQUITY SERVICES, LLC | 11K | $46K | +0.1% | 0.207% | 0.00% |
| 12 | Merck & Co., Inc. | 10K | $41K | 0.0% | 0.185% | 0.01% |
| 13 | UBS Group AG | 2K | $9K | +40.2% | 0.043% | 0.00% |
| 14 | RHUMBLINE ADVISERS | 202 | $822 | 0.0% | 0.004% | 0.00% |
| 15 | MORGAN STANLEY | 58 | $236 | 0.0% | 0.001% | 0.00% |
| 16 | FNY Investment Advisers, LLC | 27K | $107 | 0.0% | 0.490% | 0.05% |
| 17 | Virtu Financial LLC | 12K | $49 | β | 0.222% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in NEUP β a direct measure of their conviction.
Filings activity in NEUP during Q1 2026, grouped by how each filer changed its position.
6 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 17 | 19% | 27.32% | +3.70 pp | $6M | +16% |
| Q4 2025 | 21 | +40% | 23.62% | +13.88 pp | $6M | +143% |
| Q3 2025 | 15 | +50% | 9.74% | +4.40 pp | $2M | +82% |
| Q2 2025 | 10 | +25% | 5.34% | +1.38 pp | $1M | +35% |
| Q1 2025 | 8 | 11% | 3.96% | +2.80 pp | $1M | +242% |
| Q4 2024 | 9 | β | 1.16% | β | $0M | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying NEUP stock.
Based on Q1 2026 13F filings, institutional ownership of Neuphoria Therapeutics Inc. stands at 27.3%, held across 17 reporting institutions.
Lynx1 Capital Management LP is the largest reported institutional holder of NEUP, with approximately 875,328 shares worth $0.00B as of Q1 2026.
Yes β 1 widely-followed marquee investor appear among the top 25 institutional holders of NEUP, including CITADEL ADVISORS LLC.
Our composite Smart Money Score for NEUP is 50 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
4 institutions opened new positions in NEUP during Q1 2026, while 8 fully exited. 12 added to existing positions and 1 trimmed.
NEUP institutional ownership rose by 3.70 percentage points quarter-over-quarter, with a net change of -4 holders.
The top 10 institutions account for 98.5% of all reported 13F value in NEUP, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Neuphoria Therapeutics Inc. (NEUP) Institutional Ownership